Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Proteomics technologies for cancer liquid biopsies

Fig. 2

Proteomics-based cancer liquid biopsy for translational medicine. A workflow of clinical biomarker discovery divided into three stages (biomarker screening, candidate selection, and large-scale validation and implementation). Untargeted and targeted routes for biomarker exploratory with their analytical scopes are shown. Intensities of the blue color denote their probable significance at individual stages

Back to article page